Every PMCPA ruling since 2005 — searchable and filterable by company, clause, and ABPI Code version.
Case Library Membership
Search free — but unlock advanced filters to find every case involving a specific company or clause.
Already a member? Sign in →
Case Library Membership
inc. VAT
inc. VAT · cancel any time
Secure payment via Stripe
Need access for your team?
Company licences available for compliance teams, medical affairs, and training programmes.
Get a team quote →1,930 cases found
Pfizer’s UK website press release about Paxlovid used a dark grey (not black) ▼ symbol. Panel ruled breach of Clause 5.1 (high…
Novartis breached the ABPI Code after a Leqvio webinar registration page displayed the adverse event reporting statement in a position/font size that…
Small Pharma’s open-access website discussed psychedelic pipeline programmes using strong, unqualified language without clearly identifying the intended audience. PMCPA ruled a breach…
PMCPA found Galapagos’ Jyseleca website homepage banner ‘Strength of balance’ was ambiguous and insufficiently explained, breaching Clause 6.1. ‘Delivering breakthroughs…’ drew concern…
AstraZeneca was ruled in breach of Clause 8.1 after the Forxiga diabetes webpage differed between desktop and mobile (audience banner shown on…
Novartis’ Mayzent dosing webpage referenced initiation/ECG monitoring for patients with MI/heart failure history but didn’t make clear the absolute 6‑month contraindication. Breaches…
Complaint alleged disguised promotion of MSD’s chickenpox vaccine via Politico London Playbook and stopthespots.co.uk. Panel ruled no breach (Clauses 3.6, 5.1) as…
Novartis-funded HF virtual meeting was deemed promotional despite being classed non-promotional. Meeting write-up promoted Entresto but omitted prescribing info, AE reporting and…
Kesimpta promo webpage implied unrestricted SMC approval (restriction not in immediate view). A UK HCP banner ad omitted “adult” from the licence…
Novartis’ HCP website claim “THINK Symptom-free” for Xolair in CSU was ruled misleading and unsubstantiated (Clauses 6.1, 6.2, 5.1). Other claims (“UNLOCK…
Complaint alleged Novartis press releases on its UK website promoted licensed and pre-licensed medicines to HCPs/public without PI/AE statements and amounted to…
A Symbicort Turbohaler promotional email subject line omitted the non-proprietary name at first mention. PMCPA found breaches of Clauses 12.3 and 5.1,…
Complaint alleged an email invite promoted Mayzent outside its licence, was uncertified, and didn’t clearly restrict access to HCPs. PMCPA ruled no…
An SMC guidelines summary card for Nilemdo/Nustendi implied use with any statin dose. The simvastatin >40mg contraindication was only in prescribing info,…
Employee alleged a manager suggested “dressing down” to avoid looking like a rep and access hospitals during Covid. PMCPA found insufficient evidence…
Our PMCPA rulings expert has knowledge of over 1,900 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.
